Elevation Oncology CSO David Dornan resigns effective Feb 17, 2025; to assist as consultant

Elevation Oncology, Inc.

Chief Scientific Officer David Dornan, Ph.D., resigns effective February 17, 2025.
Resignation is not based on any disagreement with the company on any matter.
Dornan will continue to assist Elevation Oncology as a consultant to support transition.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Dornan

Chief Scientific Officer

Elevation Oncology, Inc.

Effective: 2025-02-17
Filed: January 31, 2025, 6:59 PM ET

On January 29, 2025, David Dornan, Ph.D., Chief Scientific Officer of Elevation Oncology, Inc. (the “Company”), informed the Company that he is resigning to pursue another opportunity, effective February 17, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Dornan resigned as Chief Scientific Officer at Elevation Oncology, Inc..

Action: resigned
Role: Chief Scientific Officer

Exact text from the filing

On January 29, 2025, David Dornan, Ph.D., Chief Scientific Officer of Elevation Oncology, Inc. (the “Company”), informed the Company that he is resigning to pursue another opportunity, effective February 17, 2025.

View on SEC.gov

Source: SEC EDGAR

accession 0001558370-25-000574

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.